{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:19:45Z","timestamp":1788779985906,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clinthera.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:09:44Z","timestamp":1653160184000},"page":"886-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1"],"prefix":"10.1016","volume":"44","author":[{"given":"Sarah-Jane","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"van Doornewaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominy","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.04.007_bib0001","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. 2015. https:\/\/www.fda.gov\/media\/86284\/download. Accessed December 17, 2021."},{"key":"10.1016\/j.clinthera.2022.04.007_bib0002","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0003","unstructured":"Whelton NJ, Phillippo DM, Owen R, et\u00a0al. DSU Report. CHTE2020 Sources and Synthesis of Evidence; Update to Evidence Synthesis Methods. March 2020."},{"key":"10.1016\/j.clinthera.2022.04.007_bib0004","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0005","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0008","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.3390\/cancers12123648","article-title":"A matching-adjusted indirect comparison of pembrolizumab\u00a0+\u00a0chemotherapy vs. nivolumab\u00a0+\u00a0ipilimumab as first-line therapies in patients with PD-L1 TPS \u22651% metastatic NSCLC","volume":"12","author":"Halmos","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0009","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s12325-020-01298-x","article-title":"Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0011","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/14787210.3.5.815","article-title":"Treatment strategies for highly treatment-experienced HIV-infected patients","volume":"3","author":"Luber","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0012","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/guidelines-adult-adolescent-arv.pdf. Accessed December 19, 2021."},{"key":"10.1016\/j.clinthera.2022.04.007_bib0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","article-title":"Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1","volume":"35","author":"Ackerman","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0014","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0016","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0017","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0018","first-page":"37","article-title":"Interpreting resistance data for HIV-1 therapy management\u2014know the limitations","volume":"8","author":"Van Laethem","year":"2006","journal-title":"AIDS Rev"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0019","unstructured":"ClinicalTrials.gov. A study to assess dolutegravir in HIV-infected subjects with treatment failure on an integrase inhibitor containing regimen (VIKING-3). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01328041. Accessed December 10, 2021."},{"key":"10.1016\/j.clinthera.2022.04.007_bib0020","series-title":"Paper presented at: 12th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance","article-title":"Durable efficacy and limited integrase resistance evolution in subjects receiving dolutegravir after failing prior integrase inhibitor (INI) regimens: week 48 results from VIKING-3","author":"Vavro","year":"2014"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0021","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"\u202f\u202fSurvival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0022","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0023","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1038\/s41598-017-10105-7","article-title":"Prognosis of HIV patients receiving antiretroviral therapy according to CD4 counts: a long-term follow-up study in Yunnan, China","volume":"7","author":"Ren","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0024","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkh157","article-title":"Benefits and limitations of testing for resistance to HIV drugs","volume":"53","author":"Richman","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2022.04.007_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:10Z","timestamp":1758963430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0149291822001461"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.04.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}